|Bid||339.00 x 900|
|Ask||355.20 x 800|
|Day's range||344.03 - 358.80|
|52-week range||341.03 - 555.77|
|Beta (5Y monthly)||0.89|
|PE ratio (TTM)||56.43|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
IRVINE, Calif. & AMSTERDAM, January 10, 2022--Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced a multi-year partnership with Illumina, Inc. (NASDAQ: ILMN), to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina’s approach to IVD partnerships in oncology. Agendia joins Illumina’s growin
MENLO PARK, Calif., January 10, 2022--GRAIL, LLC announced a collaboration with the Knight Cancer Institute at OHSU to offer the Galleri® multi-cancer early detection blood test.
MENLO PARK, Calif. & CHARLOTTE, N.C., January 10, 2022--GRAIL, LLC, announced a collaboration with Premier, Inc.’s PINC AI™ to support patient access to the Galleri® multi-cancer early detection blood test.